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Human colon cancer can be well screened using a multidiscipli-
nary panel (Jednak and Nostrant, 1998), although it is the third
most commonly diagnosed cancer and the second leading cause of
cancer death in Japanese women. Initiation and progression of
colon cancer are related to a series of mutations involving several
oncogenes (Cho and Vogelstein, 1992). The growth of solid
tumours beyond a certain critical volume and the development of
tumour metastasis is related to the establishment of vasculature
that nourishes the tumour cells. Recently, various studies have
shown that some tumour-associated genes are involved in the
regulation of angiogenesis. For example, mutant p53 potentiates
protein kinase C induction of vascular endothelial growth factor A
(VEGF) (Kieser et al, 1994). Other human tumour suppressor
genes including the Von Hippel Lindaw (VHL) gene and chromo-
some 10q also influence the angiogenesis-related factors (Hsu et
al, 1996; Siemeister et al, 1996). Alterations of the K-ras onco-
genes are early events in the adenoma–carcinoma sequence
(Saraga et al, 1997). A single amino-acid substitution in codon 12,
13 or 61 of the ras oncoprotein activates its p21 gene products, and
may be related to tumour aggressiveness (Andreyev et al, 1998).
The majority of colon cancers harbour point mutations in codon 12
of the K-ras oncogene. The mutated ras oncoproteins are thought
to alter the cellular signal transduction pathways (Matsuguchi and
Kraft, 1998) and to affect neoplastic growth of colon cancer.
Mutations that result in constitutive activation of the K-ras gene
are associated with reduction of colon cancer cell proliferation and
angiogenesis (Rak et al, 1995). K-ras oncogene-dependent VEGF
expression is necessary for progressive in vivo growth of cancer
cell lines (Okada et al, 1998). There is evidence that the ras
oncogene may be correlated with apoptosis (Ward et al, 1997).
Oncogenic ras triggers cell suicide through activation of a caspase-
independent cell death programme in human cancer cells (Chi et
al, 1999). Dominant negative mutants of ras oncogenes have been
shown to enhance apoptosis in erythroleukaemia cells. Therefore,
the mutated K-ras gene can become a specific modulator of
suppression of aggressiveness in colon cancer cells.
Specific gene modifications have been made using oligonu-
cleotides, and this has been shown to be an important strategy for
suppressing activated oncogenes. This strategy using oligonucleo-
tides including triplex DNAs, antisense nucleotides and ribozymes
(catalytic RNAs) offers the potential to achieve oncogene ablation
at a proximal level of gene expression (Kijima et al, 1998).
Ribozymes were initially discovered in the group 1 intervening
sequence in the pre-RNA of Tetrahymena thermophilia (Cech et
al, 1981). Highly specific activities of hammerhead ribozymes
were demonstrated and shown to inhibit the expression of specific
genes by targeting their mRNAs. The ribozymes are considered to
be better inhibitors of gene expression than non-catalytic oligo-
nucleotides. Ribozyme strategies have advantages because of their
site-specific cleavage activities and catalytic potential (Kijima et
al, 1995). Recently, ribozymes were reported to be effective
against various oncogenes (e.g. c-fos, ras, bcr-abl) (Scanlon et al,
1991; Bouffard et al, 1996) and the drug resistance genes (e.g.
MDR1). We also demonstrated that anti-mutated gene ribozymes
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mutant K-ras gene. The b-actin promoter-driven KrasRz sequence (pHb/KrasRz) was introduced into these cells (SW480/KrasRz), and we
evaluated its effects on growth of the colon cancer. The gene expression of angiogenesis-related molecules (vascular endothelial growth
factor and thrombospondin) was also estimated in SW480/KrasRz. KrasRz specifically and efficiently cleaved the mutant K-ras mRNA but not
wild-type mRNA in vitro. SW480/KrasRz showed decreased growth rate under tissue culture conditions (P < 0.01, Dunnett’s test). The
xenotransplantability of SW480/KrasRz (XeSW480/KrasRz) was significantly decreased in nude mice (P < 0.05, Fisher’s exact test). Tumour
volume of the xenografts XeSW480/KrasRz was significantly smaller than that of XeSW480/DisKrasRz (P < 0.01, Dunnett’s test). Gene
expression of VEGF was suppressed in SW480/KrasRz, while TSP1 gene expression was enhanced. The SW480/KrasRz cells showed
apoptosis-related features including nuclear condensation and DNA fragmentation. These results suggested that the hammerhead ribozyme-
mediated inactivation of the mutated K-ras mRNA induced growth suppression, apoptosis and alteration of angiogenic factor expression. 
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reversal of the malignant phenotype in cancer cells (Ohta et al,
1996; Tsuchida et al, 1998; Yamazaki et al, 1998).
In this study, we used a hammerhead ribozyme designed to
specifically cleave mutated K-ras oncogene mRNA in human
colon cancer cell lines carrying K-ras point mutations. We exam-
ined the effectiveness of this ribozyme for mutation-specific
inhibition of K-ras oncogene resulting in inhibition of angiogenic
factor and growth suppression in a colon cancer cell line. Here, we
report the therapeutic potential of anti-K-ras ribozyme against
human colon cancer.
MATERIALS AND METHODS
Cells
The SW480 human colon cancer cell line harbouring a mutant c-
K-ras oncogene was obtained from American Tissue Culture
Collection (#ATCC CCL-228; Rockville, MD, USA). The cell line
was maintained in Leibobitz’s L-15 medium (Sigma, St. Louis,
MO, USA) containing 10% fetal bovine serum (Sigma), as well as
100 IU ml–1 penicillin and 100 mg ml–1 streptomycin (Gibco BRL,
Gaithersburg, MD, USA). Total RNAs were extracted from
SW480 cells and the transformed cell line by a single-step
procedure using guanidinium isothiocyanate and acid phenol/
chloroform.
Preparation of anti-K-ras ribozymes
A hammerhead type ribozyme (KrasRz) was synthesized by 
30 cycles of PCR (Perkin-Elmer, Cetus, USA) with the 
following primers: 5¢-TAATACGACTCACTATAGCTACGCC-
CTGATGAGTCCGTGA-3¢ (RzS) and 5¢-GAGCTGTTTCGTC-
CTCACGGACT-3¢ (RzA) (Figure 1A). A disabled hammerhead
ribozyme (dis-KrasRz) was also synthesized by PCR with the
following primers: 5¢-TAATACGACTCACTATAGCTACGCCC-
TAATGAGTCCGTGA-3¢ (DRzS) and 5¢-GAGCTGTTTCGTC-
CTCACGGACT-3¢ (RzA). The disabled ribozyme contained a
single base exchange (G to A, underlined, see above; Figure 1B) in
the catalytic core, compared with the original.
We subcloned the above PCR products (ribozymes) into the
eucaryotic expression vector modified pHbApr-1 (pHb-KrasRz,
pHb-disKrasRz), containing a selectable geneticin resistance gene
(derived from pCEP4, Invitrogen, Figure 2) (Yamazaki et al,
1998). Expression of ribozymes or vectors was confirmed in the
cells by reverse transcriptase-PCR (RT-PCR) with the following
primers 5¢-CGCTCGATGCGATGTTTCGC-3¢ and 5¢-CAATCG-
GCTGCTCTGATGCC-3¢. Specific PCR products were detected
by Southern blotting with 32P-labelled oligonucleotide probes
according to a simplified hybridization procedure.
Introduction of anti-K-ras ribozymes in the colon
cancer cells
Subconfluent SW480 cells were transfected with the pHb-KrasRz
or pHb-disKrasRz by lipofecton (Lipofectin, Gibco BRL, Life
Technologies, Gaithersburg, MD, USA). Stably transfected cells
(SW480/KrasRz, SW480/disKrasRz) were selected for integration
of vector in growth media containing 400 mg ml–1 of G418
(geneticin) sulphate for 4 weeks (Sigma). G418-resistant colonies
were grown and screened for expression of the ribozymes by RT-
PCR assay with the following primers, 5¢-AGCACAGAGC-
CTCGCCTTT-3¢ and 5¢-GTCTGGATCCCTCGAAGC-3¢, and
probe 5¢-CTCACGGACTCATCAGG-3¢.
Cleavage of mutated K-ras oncogene in the colon
cancer cells
Total cellular RNA fractions were extracted from the cancer cells
and used for reverse transcription (1 mg total cellular RNA, 
100 pM random primers, Boehringer Mannheim, Germany;
reverse transcriptase, Gibco-BRL). T7 promoter-K-ras cDNA
fragments were amplified by PCR with the following primers
(Gene Amp PCR System 9600, Perkin Elmer: 5¢-TAATACGACT-
CACTATAGAACTTGTGGTAGTTGGAGCT-3¢ and 5¢-
CTATTGTTGGATCATATTCG-3¢). The ribozymes and substrate
RNAs were prepared from the cDNA templates with T7 RNA
polymerase (Stratagene, La Jolla, CA, USA) with a-32P-UTP (111
TBq mmol–1, Amersham) by in vitro transcription. Cleavage reac-
tions were performed with these RNAs (substrate:ribozyme ratio =
1:100 at 37°C, Mg2+ concentration = 0–40 mM; for 1 min–18 h in
vitro. The cleavage products were detected by autoradiography
(Kodak X-OMAT AR) (Scanlon et al, 1995).
Angiogenesis-related factor gene expression
We examined the gene expression levels of various angiogenic
factors in SW480/KrasRz and SW480/disKrasRz cells by
Northern blotting analysis. Total RNA (20 mg) blots on nylon
membranes (Gene Screen Plus, New England Nuclear) were
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cleavage site no cleavage reaction AB
Figure 1(A) Schematic structure of substrate-ribozyme (KrasRz) complex.
The arrowhead indicates the cleavage site. (B) The circled guanine
nucleotide was changed to adenine in the disabled ribozyme (disKrasRz)
Figure 2 Structures of expression plasmids pHb-KrasRz and pHb-
disKrasRz introduced into SW480. The ribozyme and disabled ribozyme
structures were cloned at the sites designated as ‘PCR fragment’. The
ribozyme sequences were driven by the b-actin promoter in the plasmids
Sal I Hind II
Ribozyme
neo SV 40 poly A b-actin promoter
pH b-Apr-1 plasmid (10 kb)hybridized with 32P-labelled cDNA probes for VEGF-A, B and C,
TSP-1 and 2 and BAI-1 as described previously (Tokunaga et al,
1998a; 1998b; 1999; Fukushima et al, 1998). The levels of VEGF-
A and TSP1 gene expression were estimated by densitometry
(Interactive Build Analysis System, Zeiss, Tokunaga et al, 1998b).
Growth of colon cancer xenografts
The stable transformants (SW480/KrasRz cells, SW480/
disKrasRz, SW480/vector; 5 ´ 105 cells) and parental cell line
(SW480: 5 ´ 105 cells) were subcutaneously inoculated into nude
mice (n = 10 for each transformant and the parental cell line,
female, 8 weeks, BALB/cA-nu, Clea Japan Inc., Tokyo). The
growth rates of the cells were estimated by measuring the size of
tumour lesions after inoculation. The size was calculated by the
equation, V = 0.5 ´ A ´ B2, in which A and B are the experimental
measurements in mm of length and width, respectively.
All experiments on laboratory animals were performed in accor-
dance with the care and use guidelines of the Central Institute for
Experimental Animals.
Histological examination of growth fraction in the colon
cancer xenografts
We estimated growth fraction of the cells by bromodeoxyuridine
(BrdU) incorporation. Tumours were removed from the mice under
deep anaesthesia 2 h after intraperitoneal inoculation with 100 mg
kg–1 of BrdU (Sigma Chemical Company Ltd). Removed tumours
were fixed in 10% formalin at room temperature for 24 h. Sections
(3 mm thick) of the tumours were incubated with rat monoclonal
anti-BrdU antibody (Sera-Lab. 1:40) for 45 min, after blocking of
endogenous peroxidase, treatment with 2N-HCl for 30 min and
0.05% tyrosine for 15 min for retrieval of BrdU-antigenicity. The
sections were then incubated with horseradish peroxidase (HRP)-
conjugated rabbit anti-rat IgG (Dako, 1:200) for 30 min. Reaction
products were visualized with 3,3¢-diaminobenzidine with H2O2.
The numbers of BrdU-positive cells were counted in three different
visual fields under a light microscope at a magnification of ´ 450.
Cytochemical analysis to observe apoptosis
A multistage process of apoptotic DNA fragmentation was
confirmed by the terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP-biotin nick end-labelling method (TUNEL) using
an ApopTaq Plus In Situ Apoptosis Detection Kit (Oncor,
Gaithersburg, MD, USA). The SW480 cells on chamber slides
were fixed with neutral-buffered formalin for 10 min, washed in
phosphate-buffered saline (PBS), and quenched in 2% hydrogen
peroxide for 5 min at room temperature. The specimens were then
immersed in TdT buffer for 10 min at room temperature, reacted
with a mixture of digoxigenin-labelled nucleotides and TdT
enzyme for 60 min at 37°C, and treated with anti-digoxigenin
antibody peroxidase conjugate for 30 min at room temperature.
Apoptosis was detected by colour development using 3,3-
diaminobenzidine tetrahydrochloride.
Transmission electron microscopy
The frozen sections of tumours treated with modified Karnovsky
solution (2% PFA, 0.5% glutaraldehyde, 40 mM phosphate buffer,
pH 7.4, 150 mM NaCl) for 24 h, and post-fixed with 1% OsO4 for
1 h at room temperature. The sections were dehydrated in ethanol
and embedded in Quetol-812 (Nisshin EM, Tokyo, Japan).
Ultrathin sections were stained with uranyl acetate and lead citrate,
then examined with a transmission electron microscope (Model
JEM-1200EX, JEOL, Tokyo, Japan).
Statistical analysis
The statistical significance of differences in mean tumour volume
and cell growth among the groups were examined by ANOVA, 
and significance was estimated by multiple comparison method
according to Dunnett’s test. The Fisher’s exact test was applied for
comparisons in xenotransplantability between group frequencies.
RESULTS
Cleavage of mutant K-ras oncogene transcripts in a
cell-free system
To examine the enzymatic activity and specificity of this anti-K-
ras ribozyme (KrasRz), we carried out in vitro cleavage reactions
in a cell-free system (Figure 3). The KrasRz ribozyme specifically
cleaved the GUU-mutated triplet at codon 12 of K-ras, which is
present in the colon cancer cell line SW480. In vitro cleavage
efficiency was dependent on the Mg2+ concentration and the
ribozyme/K-ras RNA ratio (data not shown). In contrast, KrasRz
did not cleave the GGU wild-type triplet at codon 12 of K-ras
derived from normal colonic mucosal cells. The disabled ribozyme
(disKrasRz) did not cleave mutant K-ras RNA in vitro.
Growth inhibition of the colon cancer cells by 
anti-K-ras ribozyme
In cell culture, these transformants showed similar morphological
features to the parental cell line, while the ribozyme-transfectant
(SW480/KrasRz) showed significantly decreased mitotic activity.
The transformants were plated at a density of 5 ´ 10 000 cells 
per dish. For generation time assay, experiments were performed
twice in duplicate. Growth of SW480/KrasRz was significantly
suppressed in culture. In contrast, the SW480/disKrasRz and
SW480 cells did not show any significant growth suppression.
Generation time of the SW480/KrasRz cells (49 h) was signifi-
cantly prolonged by 2.1-fold compared to the SW480 cells (24 h)
(Figure 4A, P < 0.01, Dunnett’s test).
To determine the effects of KrasRz on tumour formation,
SW480/KrasRz cells were inoculated into nude mice (5 ´ 105 cells
per mouse). Only two tumours (2/10) had formed 25 days after
inoculation with XeSW480/KrasRz, whereas tumours formed in
almost all mice inoculated with XeSW480/disKrasRz (10/10) and
the SW480 parental cell transfected with vector alone (10/10) and
the SW480 parental cell line (8/10) (P < 0.05, Fisher’s exact test).
The tumour volume of XeSW480/KrasRz (305 mm3) was
significantly decreased as compared with XeSW480/disKrasRz
(980 mm3) and the parental cells (1095 mm3) (on day 42 after
inoculation, 5 ´ 105 cells per mouse, P < 0.01, Dunnett’ test,
Figure 4B). The BrdU incorporation was significantly decreased in
the XeSW480/KrasRz transformants (11 ± 12) compared to
XeSW480/disKrasRz (32 ± 15) and the parental cells (41 ± 19) 
(P < 0.05, Dunnett’ test, Figure 5A,B).
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We evaluated the expression of various angiogenic factors by
Northern blotting analysis with total cellular RNA preparation 
(20 mg). Relative expression level was calculated by the ratio 
A1:A0, where each A0 and A1 is the gene expression of parental cell
or transformant respectively, standardized by rehybridization of
the b2-microglobulin gene in each cell line. The SW480/KrasRz
cells showed almost 90% reduction in levels of VEGF-A gene
expression compared to SW480/parental cells, while the expres-
sion was unchanged in SW480/disKrasRz (Figure 6A). The level
of VEGF-A-gene expression was unchanged in SW480 cells trans-
fected with pHbApr-1 vector (data not shown). The cell lines
showed no marked changes in levels of VEGF-B or C gene
expression. SW480/KrasRz cells also showed an almost 80%
increase in expression of the angiostatic factor TSP1 as compared
with SW480/disKrasRz and parental SW480 cells (Figure 6B). No
expression of the other angiostatic factors TSP2 and BAI-1 was
detected in these transformants.
Apoptosis induced by inactivation of mutant K-ras
oncogene
Oligonucleosomal DNA fragmentation or condensation was
observed in cells treated with anti-KrasRz (Figure 7). The cells
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Figure 3 Cleavage reaction of the K-ras RNA by ribozyme in vitro.
Cleavage activity of the ribozyme targeting the mutated K-ras RNA. The
ribozyme and fragment RNA were labelled with a-32P-UTP (111 TBq mmol–1).
Lane 1, anti-Kras Rz only (36 bases); Lane 2, K-ras RNA originated by
SW480 (96 bases) only; Lane 3, both anti-Kras Rz and Kras RNA. The anti-
Kras Rz cleaved K-ras RNA into two products, a 23-base 5¢-fragment and a
73-base 3¢-fragment. Lane 4, anti-disKras Rz only (36 bases); Lane 5, K-ras
RNA from SW480 (96 bases) only; Lane 6, both anti-disKras Rz and K-ras
RNA. The anti-disKras Rz did not cleave K-ras RNA
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Figure 4 Growth inhibition mediated by anti-KrasRz. (A) Relative growth of
colon cancer cell lines in culture. The cell lines were plated at 5 ´ 105. The
cell growth data shown are means ± SD of five independent plates. Each
sample was counted in triplicate. Differences among the cell lines were
determined by ANOVA. The growth rate of SW480/KrasRz was significantly
lower than those of SW480/disKrasRz or SW480 cells (P < 0.01, Dunnett’s
test). (B) Tumour volume of the xenografts of the cell lines. The tumour
volume (mm3) was determined as follows; 0.5 ´ length ´ width2. The volume
of XeSW480/KrasRz tumours was significantly less than those of
XeSW480/disKrasRz or XeSW480 (P < 0.01, Dunnett’s test)with DNA fragmentation were DAB-positive due to TdT reac-
tions. In contrast, few apoptotic cells were noted when the cells
were treated with dis-KrasRz.
DISCUSSION
In this study, we constructed a hammerhead-type ribozyme
(KrasRz) to cleave mutated K-ras mRNA transcripts in vitro and in
vivo. KrasRz specifically cleaved mutant K-ras RNA in a cell-free
system. We evaluated the biological effects of KrasRz in the
human colonic cancer cell line SW480. Our results demonstrated
that KrasRz effectively cleaved the mutant K-ras mRNA and
significantly suppressed growth of this colonic cancer cell line.
Inhibition of the function of mutant ras alleles in cancer cells by
treatment with farnesyltransferase inhibitors suppresses the
growth of solid tumours in vivo (Kohl et al, 1993). Disruption of
mutant K-ras activation by triplet DNA was associated with
growth alteration of colon cancer cell lines (Shirasawa et al, 1993).
We showed here that the inactivation of mutant K-ras mRNA by a
specific hammerhead-type ribozyme could suppress growth of a
human colonic cancer cell line in vitro and in vivo.
Angiogenesis is a major mechanism involved in the growth
and metastasis of solid tumour lesions. We reported previously
that various kinds of angiogenesis-related factors play important
Alteration of angiogenic potential by anti-K-ras ribozyme 837
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AB
Figure 5 BrdU immunoreactivity in the xenografted tumour cells. BrdU
incorporation in Xe480/disKrasRz (A) was more than that in Xe480/KrasRz
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Figure 6 Expression of angiogenic-related gene in the cell lines. (A) VEGF
gene (B) TSP1 gene. Lane 1, SW480/KrasRz cells; Lane 2,
SW480/disKrasRz cells; Lane 3, SW480 cells. The SW480/KrasRz cells
showed suppressed level of VEGF gene expression compared with
SW480/disKrasRz or SW480 cells, while the SW480/KrasRz cells showed
increased level of TSP1 gene expression compared with SW480/disKrasRz
or SW480 cells
C
Figure 7 Histological features of apoptotic cells mediated by anti-KrasRz.
(A) The SW480/KrasRz cells showed DAB-positive due to TdT reactions (B)
while the SW480/disKrasRz cells did not (´ 150). (C) Xe480/KrasRz showed
nucleosomal DNA fragmentation (arrow) and apoptotic body by electron
microscopy (´ 4000)
ABroles in malignant features including tumour size, stromal vascu-
larity and distant metastasis of various cancers (Tokunaga et al,
1998a; Tomisawa et al, 1999; Tsuchida et al, 1999). Expression
of the cell-associated isoform of VEGF-A, VEGF189, was
significantly correlated with liver metastasis in colonic cancers
(Tokunaga et al, 1998a). VEGF189 expression was also corre-
lated with growth of non-small cell lung cancer and renal cell
carcinoma (Oshika et al, 1998; Tomisawa et al, 1999). On the
other hand various angiostatic factors affect the vascularization
and growth of solid tumours (Oshika et al, 1999; Tokunaga et al,
1999). TSP1 expression was correlated with tumour size of
colonic cancer (Tokunaga et al, 1998b). These studies suggested
the VEGF-A and TSP were major factors involved in vascular-
ization and growth of human solid tumours.
In this study, attenuation of activated K-ras oncogene by a
hammerhead-type ribozyme, KrasRz, decreased VEGF-A gene
expression in the colonic cancer cell line SW480
(SW480/KrasRz), but did not affect VEGF-B or C gene expres-
sion. VEGF-A gene expression of the angiostatic factor TSP1 was
simultaneously increased in SW480/KrasRz. These alterations of
angiogenic phenotype induced by the ribozyme were responsible
for reduced vascularization of the tumour. It has been reported that
angiogenic phenotype was affected by the accumulation of
sequential mutations in multiple genes, including the activation of
oncogenes or the ablation of a tumour suppressor gene (Rak et al,
1995; Volpert et al, 1997). Production of VEGF is stimulated by
ras in NIH3T3 fibroblasts and in intestinal cell lines (Grugel et al,
1995; Rak et al, 1995). Transfection with activated ras decreased
the level of inhibitory TSP1 in bronchial epithelial cells
(Zabrenetzky et al, 1994). Wild-type p53 downregulated endoge-
nous VEGF mRNA in a human glioma cell line and a human fetal
kidney cell line (Mukhopadhyay et al, 1995). We also reported that
accumulation of p53 protein was inversely correlated with TSP1
expression (Tokunaga et al, 1998b). These results suggested that
alteration of angiogenesis-related factor expression was achieved
by modulation of expression of various oncogenes or oncosup-
pressor genes. The downregulation of mutant K-ras oncogene by
anti-Kras ribozyme (KrasRz) significantly suppressed angiogenic
features with decreased VEGF-A and increased TSP1, whereas
expression of other angiogenic factors (VEGF-B and C) and
angiostatic factors (TSP2 and BAI-1) was not affected. The mech-
anisms responsible for the regulation of angiogenic features are
complex.
The ras gene seems to be a good candidate for targeting of onco-
gene modulation by ribozymes. Anti-ras ribozymes have been
tested in several tumour types. Anti-H-ras ribozyme showed
marked growth inhibition and suppression of tumorigenicity in a
bladder carcinoma cell line (Feng et al, 1995). The bladder carci-
noma cell line transfected with anti-H-ras ribozyme showed
limited invasion and longer overall survival. The attenuation of K-
ras gene expression by anti K-ras ribozyme inhibited growth of a
pancreatic cell line. In this study, anti-K-ras ribozyme (KrasRz)
showed similar effects on a colonic cancer cell line with a K-ras
mutation. The results presented here indicate that mutant K-ras
gene increases the growth of colon cancer cells by reduction of
apoptosis and enhancement of angiogenesis in vivo. We demon-
strated that an anti-K-ras ribozyme induced apoptosis in a
pancreatic cancer cell line (Tsuchida et al, 2000). In this study, 
we demonstrated apoptotic changes induced by the anti-K-ras
ribozyme in a colon cancer cell line. The results suggested that the
ribozyme-mediated inactivation of mutant K-ras oncogene
resulted in growth suppression, via apoptosis of various cancer
cells, and a shift in the angiostatic conditions in the cancer stroma.
Reduced proliferation seemed to be a major factor affecting
growth reduction of the SW480/KrasRz. The mitotic activity or
fractions of BrdU-positive cells were clearly decreased in
SW480/KrasRz in the xenografts compared to SW480/disKrasRz,
while the apoptotic changes were definitive in certain cells in
SW480/KrasRz. The tumour growth suppression by the anti-K-ras
ribozyme was achieved by a combination of the above factors.
Further analysis and improvements are required for therapeutic
application of the anti-K-ras ribozyme (KrasRz) in human colon
cancer. Such studies may lead to new therapeutic strategies espe-
cially for management of vascular invasion and distant metastasis
of colon cancer.
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